- Home
- BRKR vs RGEN Comparison
BRKR vs RGEN Comparison
Compare BRKR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- RGEN
- Stock Information
- Founded
- BRKR 1960
- RGEN 1981
- Country
- BRKR United States
- RGEN United States
- Employees
- BRKR N/A
- RGEN N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- RGEN Medical/Dental Instruments
- Sector
- BRKR Industrials
- RGEN Health Care
- Exchange
- BRKR Nasdaq
- RGEN Nasdaq
- Market Cap
- BRKR 6.3B
- RGEN 8.0B
- IPO Year
- BRKR 2000
- RGEN N/A
- Fundamental
- Price
- BRKR $42.13
- RGEN $127.47
- Analyst Decision
- BRKR Buy
- RGEN Buy
- Analyst Count
- BRKR 12
- RGEN 12
- Target Price
- BRKR $54.50
- RGEN $170.40
- AVG Volume (30 Days)
- BRKR 2.3M
- RGEN 694.0K
- Earning Date
- BRKR 08-05-2025
- RGEN 07-29-2025
- Dividend Yield
- BRKR 0.47%
- RGEN N/A
- EPS Growth
- BRKR N/A
- RGEN N/A
- EPS
- BRKR 0.52
- RGEN N/A
- Revenue
- BRKR $3,446,100,000.00
- RGEN $650,429,000.00
- Revenue This Year
- BRKR $6.43
- RGEN $13.93
- Revenue Next Year
- BRKR $4.21
- RGEN $14.35
- P/E Ratio
- BRKR $80.87
- RGEN N/A
- Revenue Growth
- BRKR 14.84
- RGEN 4.88
- 52 Week Low
- BRKR $34.10
- RGEN $102.97
- 52 Week High
- BRKR $72.94
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- BRKR 63.12
- RGEN 54.11
- Support Level
- BRKR $40.71
- RGEN $121.44
- Resistance Level
- BRKR $43.21
- RGEN $131.43
- Average True Range (ATR)
- BRKR 1.70
- RGEN 4.47
- MACD
- BRKR 0.37
- RGEN 0.61
- Stochastic Oscillator
- BRKR 87.46
- RGEN 74.57
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.